Skip to main content

Bruker to Pocket at Least $14.7M in Stock Offering

NEW YORK (GenomeWeb News) — Bruker BioSciences today said it expects to pocket at least $14.7 million after issuing a stock offering.
The company said proceeds from the sale may be used for general purposes, repaying debts, and potential acquisitions. 
The company said it expects to sell 10.4 million shares at $7.10 apiece. Bruker said it expects selling stockholders to earn roughly $54.9 million. 
Bruker said 2.2 million shares will be sold through the company and 8.2 million will be offered through four stockholders. 
Bruker said it also has offered underwriters an option to buy an additional 330,000 shares, and selling stockholders have offered an option to buy 1.23 million shares.
This additional offering should bring in an extra $2.2 million for the company and $8.3 million for the stockholders.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.